Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03129620 · ClinicalTrials.gov registry record

Pharmacokinetics of Ampicillin in Neonates With Moderate to Severe Hypoxic-Ischemic Encephalopathy

A clinical trial of Hypothermia, sponsored by Drexel University.

Completed
Registry status
14
Enrollment target
1
Study location

NCT03129620 is a study of Hypothermia that has completed, run by Drexel University. The registered enrollment target is 14 participants, below the 47-participant average among 9 other Hypothermia trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03129620, a study of Hypothermia, has completed, sponsored by Drexel University.

COMPLETED
Registry status
14 participants
Enrollment target
1
Study location

Study Summary

Controlled Hypothermia has become the standard of care for neonates with moderate to severe HIE. Ampicillin and aminoglycosides are drugs that are universally used for the treatment of suspected neonatal sepsis, which may or may not be responsible for the etiology of HIE. Currently, medication dosage regimens are not altered in the setting of CH. A better understanding of the effects of our interventions on this unique population may help us tailor our therapy to the specific circumstances of the patient

Conditions Studied

Study Locations (1)

Pennsylvania

  • St Christopher's Hospital for children - Philadelphia

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2013-03
Est. Completion 2016-04

Sponsor

Drexel University

92 total trials

What the Registry Record Tells You About NCT03129620

The ClinicalTrials.gov registry entry for NCT03129620 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 47-participant average among 9 other Hypothermia trials with a reported enrollment target (70% lower). The listed sponsor is Drexel University, which has 92 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypothermia appearing as the primary indexed condition, and to 0 interventions.

NCT03129620 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03129620 about?

NCT03129620 is a clinical study titled "Pharmacokinetics of Ampicillin in Neonates With Moderate to Severe Hypoxic-Ischemic Encephalopathy". Controlled Hypothermia has become the standard of care for neonates with moderate to severe HIE. Ampicillin and aminoglycosides are drugs that are universally used for the treatment of suspected neonatal sepsis, which may or may not be responsible for the etiology of HIE. Currently, medication dosag...

What is the current status of trial NCT03129620?

This trial is currently completed. The enrollment target is 14 participants. The study started on 2013-03. Estimated completion is 2016-04.

What conditions does trial NCT03129620 study?

This clinical trial studies the following conditions: Hypothermia.

Who is sponsoring clinical trial NCT03129620?

This trial is sponsored by Drexel University, which has 92 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03129620 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypothermia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.